AAV ANCA-associated vasculitis Wegner
Conditions
Interventions
None listed
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age between 18 and 70 years old. Positive AAV diagnosis.
Exclusion criteria
Exclusion criteria: Lack of informed consent Current infection CKD stage 5 or dialysis Pregnancy Active cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. What are the differences in the transcriptome of circulating monocytes from AAV patients when the disease is in remission or when the disease is active (flares), and how does this differ with the transcriptome of circulating monocytes from healthy individuals? 2. What are the differences in the epigenome of circulating monocytes from AAV patients when the disease is in remission or when the disease is active (flares), and how does this differ with the epigenome of circulating monocytes from healthy individuals? 3. What are the differences in the cytokine response of circulating monocytes from AAV patients when the disease is in remission or when the disease is active (flares), and how does this differ with the response of circulating monocytes from healthy individuals? | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Are there correlations between the trained immunity profile of circulating monocytes (identified by transcriptome, epigenetics, and cytokine response) and the degree of current disease activity in clinical variables of AAV patients? 2. Are there correlations between the trained immunity profile of circulating monocytes (identified on the basis of the transcriptome, epigenetics, and cytokine response) and the risk of the occurrence of flares in the future. 3. Are there correlations between the trained immunity profile of circulating monocytes (identified based on the transcriptome, epigenetics, and cytokine response) and inflammatory markers in the blood. | — |
Countries
Netherlands
Outcome results
None listed